Aβrain

ABrain is a South Korean biotechnology company specializing in the development of next-generation gene therapies for neurodegenerative diseases. The company's proprietary platform technology, NACI (Non-self-Assembling and Competitive Inhibition), is designed to engineer peptides that competitively inhibit the aggregation of pathological proteins without self-accumulating. ABrain's pipeline includes AAV-based gene therapies targeting key proteins associated with Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Its lead candidate, AB103, is an AAV-delivered gene therapy designed to inhibit alpha-synuclein aggregation and is currently in preclinical development with support from the Korea Drug Development Fund (KDDF).